(Q36263113)

13 August 2017

1 reference

title

Current therapy for hepatitis C. (English)

1 reference

13 August 2017

Mireen Friedrich-Rust

series ordinal

1

object named as

Mireen Friedrich-Rust

1 reference

13 August 2017

2

Stefan Zeuzem

1 reference

13 August 2017

Christoph Sarrazin

3

1 reference

13 August 2017

21 September 2005

1 reference

International Journal of Colorectal Disease

13 August 2017

1 reference

13 August 2017

22

1 reference

13 August 2017

4

1 reference

13 August 2017

341-349

1 reference

https://scigraph.springernature.com/pub.10.1007/s00384-005-0038-9

13 August 2017

0 references

cites work

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00384-005-0038-9

Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00384-005-0038-9

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

21 January 2018

1 reference

12 December 2020

[Criteria for the definition of acute and chronic hepatitis C]

1 reference

12 December 2020

Standardization of hepatitis C virus RNA quantification

1 reference

12 December 2020

Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays

1 reference

12 December 2020

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

1 reference

12 December 2020

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study

1 reference

12 December 2020

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

1 reference

12 December 2020

[Standard treatment of acute and chronic hepatitis C]

1 reference

12 December 2020

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

12 December 2020

[Diagnosis, progression and therapy of hepatitis C virus infection as well as viral infection in children and adolescents--results of an evidenced based consensus conference of the German Society for Alimentary Metabolic Disorders and and in coopera

1 reference

12 December 2020

Highly sensitive hepatitis C virus RNA detection assays for decision of treatment (dis)continuation in patients with chronic hepatitis C.

1 reference

12 December 2020

National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C 2002 (June 10-12, 2002)

1 reference

12 December 2020

Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis

1 reference

12 December 2020

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

12 December 2020

Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3.

1 reference

12 December 2020

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

12 December 2020

Therapy of acute hepatitis C.

1 reference

12 December 2020

Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups

1 reference

12 December 2020

Quantitation of hepatitis C virus RNA by third generation branched DNA-based signal amplification assay

1 reference

12 December 2020

Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.

1 reference

12 December 2020

National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002--June 10-12, 2002.

1 reference

12 December 2020

Treatment of acute hepatitis C with interferon alfa-2b

1 reference

12 December 2020

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

1 reference

12 December 2020

Pharmacokinetics of peginterferons

1 reference

12 December 2020

Triple therapy with amantadine in treatment-naive patients with chronic hepatitis C: a placebo-controlled trial

1 reference

12 December 2020

Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD).

1 reference

12 December 2020

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment

1 reference

12 December 2020

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

12 December 2020

Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy

1 reference

12 December 2020

Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels

1 reference

12 December 2020

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

12 December 2020

Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C.

1 reference

12 December 2020

Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report

1 reference

12 December 2020

High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection

1 reference

12 December 2020

Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4.

1 reference

12 December 2020

Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance.

1 reference

12 December 2020

Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load

1 reference

12 December 2020

Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C.

1 reference

12 December 2020

Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy.

1 reference

12 December 2020

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

1 reference

12 December 2020

Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression

1 reference

12 December 2020

10.1007/S00384-005-0038-9

Identifiers

DOI

1 reference

13 August 2017

1 reference

PubMed ID

16175369